Will Indaptus Therapeutics stock go up?

According to Danelfin AI, Indaptus Therapeutics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.07%) is -12.75% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Indaptus Therapeutics stock?

The Indaptus Therapeutics target price is $8.68 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Indaptus Therapeutics stock right now?

Indaptus Therapeutics has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (38.07%) is -12.75% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Indaptus Therapeutics stock is a good buy .

Is Indaptus Therapeutics undervalued right now?

Based on analysts, the average price target upside for Indaptus Therapeutics is +193.26% (1Y). According to Danelfin AI, Indaptus Therapeutics has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Indaptus Therapeutics stock over the past 12 months?

The Indaptus Therapeutics stock price range over the past 12 months has been $1.06 - $14.

What is going on with Indaptus Therapeutics stock in the last 3 months?

The Indaptus Therapeutics stock performance in the last quarter has been +62.63%.

Does Indaptus Therapeutics offer dividend payments?

No, Indaptus Therapeutics does not currently pay dividends.

What is the current market capitalization of Indaptus Therapeutics?

Indaptus Therapeutics's market cap is $332.94M, as of 2026-07-02 08:00.

When is the next INDP earnings report date?

INDP will publish its next earnings report on 2026-05-15.

Indaptus Therapeutics Inc (INDP) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

INDP AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Indaptus Therapeutics Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 38% probability of outperforming the market in the next 3 months, which is 13% lower than the average probability of any stock (51%). This low probability is driven by several significant detractors. The aggregated impact of fundamental signals not detailed in the report weighs down the probability by -2.00%, while the stock's technical chart patterns across multiple timeframes (252, 120, 504, and 90 days) collectively detract. Other major negative influences include low Institutional Ownership (in the bottom 10%), a low Fear & Greed Index reading of 31, and a low Beginning Cash position (in the bottom 20%). Notable data points that contribute to this weak outlook include the stock's high Maximum Volatility (in the top 10%), indicating significant risk, and its classification in the Biotechnology industry, which also detracts from the probability. On a more positive note, the stock's Performance (Last Market Day) was strong (in the top 10%), adding +0.45% to the probability, and its Alpha Last Day also provided a small boost of +0.68%. However, these short-term positive signals are heavily outweighed by the numerous and substantial negative factors across fundamentals, ownership, cash position, and technical patterns, painting an overall picture of high risk and low probability of market-beating returns.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum-3.55%
Direction and strength of recent price movements
Sentiment-2.70%
How analysts and the market view the stock
Valuation-2.54%
How the stock is priced relative to its fundamentals
Volatility-2.46%
How much the stock price tends to fluctuate
Size & Liquidity-1.25%
Company size and trading liquidity
Earnings Quality-0.25%
Stability and reliability of reported earnings

INDP probability advantage of beating the market (3M):

-12.75%

AI Score

Strong Sell

Indaptus Therapeutics (INDP) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -12.75% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of INDP (38.07%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
INDP probability advantage of beating the market (3M)-12.75%
INDP probability of beating the market (3M)38.07%

INDP probability advantage of beating the market (3M): -12.75%

The AI-powered overall analysis of Indaptus Therapeutics (INDP) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of INDP:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-2.00%
Technical	Chart Pattern (252d)	figure_8	N/A	-1.30%
Sentiment	Institutional Ownership	0.07%	N/A	-1.26%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.25%
Fundamental	Beginning Cash (Millions)	8.51		-1.25%
Technical	Maximum Volatility	13.61%		-1.13%
Technical	Chart Pattern (120d)	figure_148	N/A	-1.08%
Technical	Chart Pattern (504d)	figure_6	N/A	-0.89%
Technical	Chart Pattern (90d)	figure_14	N/A	-0.83%
Technical	Alpha Last Day	-0.01%		+0.68%
Fundamental	Upgrade to unlock			-0.54%
Technical	Upgrade to unlock			+0.45%
Technical	Upgrade to unlock			-0.45%
Technical	Upgrade to unlock			+0.44%
Sentiment	Upgrade to unlock			-0.43%

Rest of Alpha Signals: -1.90%

INDP probability advantage of beating the market (3M)Total:-12.75%
INDP AI Score

Significant changes Vs previous day

INDP Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.96
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

INDP Proven Sell Signal & Price Forecast

This is the price chart for INDP from January 2, 2026 until today. The chart indicates, in red, the 112 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

INDP Average Past Performance & Loss Rate

Three months after its 1332 Sell signals since July 2026, INDP had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

1332 Past INDP Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-33.54%
Average Alpha				-47.86%
Loss Rate (% Negative Perf.)				73.47%
% Negative Alpha				83.17%

INDP Frequently Asked Questions

Will Indaptus Therapeutics stock go up?
According to Danelfin AI, Indaptus Therapeutics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.07%) is -12.75% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Indaptus Therapeutics stock?
Is it a good time to buy, sell, or hold Indaptus Therapeutics stock right now?
Is Indaptus Therapeutics undervalued right now?
What was the price range of Indaptus Therapeutics stock over the past 12 months?
What is going on with Indaptus Therapeutics stock in the last 3 months?
Does Indaptus Therapeutics offer dividend payments?
What is the current market capitalization of Indaptus Therapeutics?
When is the next INDP earnings report date?

Indaptus Therapeutics Inc Company Profile

Indaptus Therapeutics, Inc., occupying the space in the clinical biotechnology sphere, is devoted to formulating immunotherapy products aimed at combatting cancer and multiple viral diseases. Its prime clinical contender is Decoy20--a compound under extensive research for its potential to activate single agent activity and/or produce long-lasting therapeutic responses in divergent cancer types such as lymphoma, hepatocellular carcinoma, colorectal and pancreatic tumors. Additionally, it's also being examined for efficaciousness against chronic hepatitis B virus and human immunodeficiency virus infections, with all these studies currently in the phase 2 of clinical trials. Formerly operating under the banner of Intec Parent Inc., they underwent a branding renewal in August 2021 to assume their current name - Indaptus Therapeutics Inc. Housing its corporate headquarters amidst the vibrant hustle of New York City, it continues to make strides towards better global health from this strategic location.

Sector:
Country:United States
Industry:
Address:3 Columbus Circle, 15th Floor, New York City
Employees:5
Website:indaptusrx.com

Pros

Novel immunotherapy mechanism of action

Broad therapeutic potential across multiple cancer types

Proprietary platform technology and intellectual property

Systemic administration for metastatic disease treatment

Potential for synergistic combination with existing therapies

Cons

Extremely high capital intensity for drug development

Binary outcomes inherent in clinical trial progression

Intense regulatory hurdles for novel biological products

Competition from established and emerging oncology treatments

Concentrated pipeline risk on a single lead candidate

Company	AI Score	Compare
ADPTAdaptive Biotechnologies Corp
ABUSArbutus Biopharma Corp
IBRXImmunitybio Inc
RCUSArcus Biosciences Inc
AGENAgenus Inc

Company	AI Score	Compare
ADPTAdaptive Biotechnologies Corp
ABUSArbutus Biopharma Corp
IBRXImmunitybio Inc
RCUSArcus Biosciences Inc
AGENAgenus Inc

INDP Stock AI Analysis High Risk